RIPK3 a novel biomarkers in cirrhosis - J of Hepatology - Jan.26

RIPK3 (Receptor-interacting protein kinase 3) is a crucial protein involved in necroptosis, a regulated form of cell death distinct from apoptosis. Necroptosis plays a significant role in inflammatory and degenerative diseases, including liver diseases such as cirrhosis, acute decompensation (AD), and acute-on-chronic liver failure (ACLF). RIPK3 is emerging as a novel biomarker in these conditions due to its strong association with disease severity, organ dysfunction, and mortality.

### Problem Statement:

Patients with cirrhosis who experience acute decompensation (AD) or progress to acute-on-chronic liver failure (ACLF) frequently develop multi-organ failure and face high mortality rates. Current prognostic models for these patients often lack precision, particularly in identifying key drivers of disease progression. Non-apoptotic forms of cell death, such as necroptosis, have been implicated in the pathophysiology of AD and ACLF, but their contribution to organ failure and mortality has not been fully understood. RIPK3, a central mediator of necroptosis, has been identified as a potential biomarker for these conditions, offering an opportunity to improve risk stratification and guide therapeutic interventions.

### Conclusion:

The study highlights RIPK3 as a key driver of organ failure and mortality in patients with AD and ACLF. Elevated plasma levels of RIPK3 were strongly associated with multi-organ dysfunction, particularly hepatic and renal failure, as well as disease progression and mortality. A mortality prediction model incorporating RIPK3 (>2.261x ULN), along with other clinical parameters like CLIF-C OF (Chronic Liver Failure Consortium Organ Failure score) and leukocytosis/leukopenia, demonstrated high accuracy in predicting outcomes. Furthermore, hepatic RIPK1 expression was found to be elevated in ACLF patients and correlated with disease severity and mortality, emphasizing the role of necroptosis originating in the liver.

This study underscores the importance of RIPK3 as a biomarker for risk stratification in AD and ACLF. By integrating RIPK3 into predictive models, clinicians can enhance their ability to identify high-risk patients and personalize therapeutic strategies targeting necroptosis. This approach has the potential to revolutionize clinical decision-making and improve outcomes for patients with these life-threatening liver conditions.